Fibrate Plus Statin May Pose Heart Risk to Women

Posted by: admin on: May 30, 2011

WASHINGTON — The FDA said it was concerned about trial data suggesting that adding a fibrate drug to a statin increased the risk of cardiac events in women and will convene an advisory committee meeting next month to review the findings.

The agency was reacting to a new analysis of the ACCORD-Lipid trial, which tested the addition of delayed-release fenofibric acid (Trilipix) to simvastatin (Zocor) in diabetic patients.
Main results from the trial, announced in March 2010, indicated that the combination did not reduce cardiovascular events relative to patients receiving only the statin drug.

Read more: http://www.medpagetoday.com/Cardiology/Dyslipidemia/26133

Leave a Reply

Your email address will not be published. Required fields are marked *

*

CMHF Accredited by Maharashtra Medical Council

Subscribe to our Posts

Enter your email address:



  • drchasrani: Difficult to get such a data, authenticated at that. Try Times of India online library
  • rakesh pore: hi, where can i get genuine information about "10 most common drugs sold in india?" i want it for a local project
  • nilesh dutta: sir, Plz give detail about MBA Sports Management Thanks and Regards

Calculate Your Body Mass Index



Check your Body Mass Index »

    Common walnut - 650 kcal in 100g
    650kcal
    Common walnut - 650 kcal in 100g
    by Noni